Incyte CorpNASDAQ:INCY
- LAST PRICE54.4300
- TODAY'S CHANGE (%)0.3500 (0.6472%)
- Bid / Lots54.4200/ 3
- Ask / Lots54.4400/ 3
- Open / Previous Close54.5000 / 54.0800
- Day Range
- 52 Week Range
- Volume636,099
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | INCY |
|---|---|---|
| 09:32 ET | 32218 | 54.65 |
| 09:34 ET | 6204 | 54.63 |
| 09:36 ET | 4000 | 54.74 |
| 09:38 ET | 3985 | 54.7 |
| 09:39 ET | 4444 | 54.66 |
| 09:41 ET | 2900 | 54.8 |
| 09:43 ET | 10211 | 54.7202 |
| 09:45 ET | 5813 | 54.66 |
| 09:48 ET | 2800 | 54.75 |
| 09:50 ET | 2800 | 54.63 |
| 09:52 ET | 800 | 54.65 |
| 09:54 ET | 2444 | 54.69 |
| 09:56 ET | 2358 | 54.61 |
| 09:57 ET | 3009 | 54.67 |
| 09:59 ET | 3694 | 54.6 |
| 10:01 ET | 23302 | 54.72 |
| 10:03 ET | 4296 | 54.7925 |
| 10:06 ET | 2661 | 54.795 |
| 10:08 ET | 3720 | 54.73 |
| 10:10 ET | 5039 | 54.75 |
| 10:12 ET | 800 | 54.76 |
| 10:14 ET | 3727 | 54.77 |
| 10:15 ET | 3615 | 54.83 |
| 10:17 ET | 5494 | 54.8 |
| 10:19 ET | 5536 | 54.7655 |
| 10:21 ET | 8830 | 54.87 |
| 10:24 ET | 4625 | 54.875 |
| 10:26 ET | 3326 | 54.88 |
| 10:28 ET | 3671 | 54.81 |
| 10:30 ET | 2815 | 54.81 |
| 10:32 ET | 1454 | 54.8 |
| 10:33 ET | 2760 | 54.79 |
| 10:35 ET | 4751 | 54.75 |
| 10:37 ET | 3283 | 54.7 |
| 10:39 ET | 5615 | 54.67 |
| 10:42 ET | 3000 | 54.59 |
| 10:44 ET | 4427 | 54.54 |
| 10:46 ET | 2653 | 54.34 |
| 10:48 ET | 7089 | 54.45 |
| 10:50 ET | 5249 | 54.39 |
| 10:51 ET | 3051 | 54.44 |
| 10:53 ET | 5255 | 54.49 |
| 10:55 ET | 3280 | 54.51 |
| 10:57 ET | 4746 | 54.41 |
| 11:00 ET | 2843 | 54.4 |
| 11:02 ET | 5188 | 54.46 |
| 11:04 ET | 3911 | 54.445 |
| 11:06 ET | 2700 | 54.38 |
| 11:08 ET | 3230 | 54.32 |
| 11:09 ET | 7425 | 54.34 |
| 11:11 ET | 3924 | 54.4 |
| 11:13 ET | 2907 | 54.39 |
| 11:15 ET | 7786 | 54.38 |
| 11:18 ET | 5776 | 54.32 |
| 11:20 ET | 4477 | 54.35 |
| 11:22 ET | 3784 | 54.39 |
| 11:24 ET | 23189 | 54.53 |
| 11:26 ET | 6809 | 54.54 |
| 11:27 ET | 4257 | 54.53 |
| 11:29 ET | 12028 | 54.44 |
| 11:31 ET | 4590 | 54.38 |
| 11:33 ET | 2170 | 54.455 |
| 11:36 ET | 1711 | 54.48 |
| 11:38 ET | 1897 | 54.4 |
| 11:40 ET | 2442 | 54.41 |
| 11:42 ET | 3743 | 54.39 |
| 11:44 ET | 2600 | 54.36 |
| 11:45 ET | 1531 | 54.37 |
| 11:47 ET | 2736 | 54.425 |
| 11:49 ET | 2260 | 54.435 |
| 11:51 ET | 5207 | 54.47 |
| 11:54 ET | 3528 | 54.44 |
| 11:56 ET | 1280 | 54.46 |
| 11:58 ET | 2415 | 54.44 |
| 12:00 ET | 5500 | 54.38 |
| 12:02 ET | 4703 | 54.41 |
| 12:03 ET | 4537 | 54.36 |
| 12:05 ET | 4009 | 54.355 |
| 12:07 ET | 2691 | 54.37 |
| 12:09 ET | 2000 | 54.35 |
| 12:12 ET | 1300 | 54.44 |
| 12:14 ET | 2741 | 54.4368 |
| 12:16 ET | 2310 | 54.45 |
| 12:18 ET | 1294 | 54.44 |
| 12:20 ET | 3935 | 54.46 |
| 12:21 ET | 3286 | 54.49 |
| 12:23 ET | 1673 | 54.465 |
| 12:25 ET | 3050 | 54.46 |
| 12:27 ET | 2500 | 54.465 |
| 12:30 ET | 2951 | 54.45 |
| 12:32 ET | 2501 | 54.455 |
| 12:34 ET | 2377 | 54.45 |
| 12:36 ET | 4256 | 54.445 |
| 12:38 ET | 2078 | 54.47 |
| 12:39 ET | 5188 | 54.445 |
| 12:41 ET | 3313 | 54.45 |
| 12:43 ET | 3277 | 54.47 |
| 12:45 ET | 1870 | 54.43 |
May 2, 2024
Incyte to Present at Upcoming Investor Conference, from 8:00AM ET on Thursday May 02, 2024 by Dow Jones
8:00AM ET on Thursday May 02, 2024 by Dow Jones
May 1, 2024
DJ Incyte Is Maintained at Buy by TD Cowen, from 2:06PM ET on Wednesday May 01, 2024 by Dow Jones
2:06PM ET on Wednesday May 01, 2024 by Dow JonesDJ Incyte Price Target Cut to $83.00/Share From $84.00 by Truist Securities, from 8:57AM ET on Wednesday May 01, 2024 by Dow Jones
8:57AM ET on Wednesday May 01, 2024 by Dow JonesDJ Incyte Is Maintained at Market Perform by BMO Capital, from 8:12AM ET on Wednesday May 01, 2024 by Dow Jones
8:12AM ET on Wednesday May 01, 2024 by Dow Jones
Apr 30, 2024
Incyte Reports 2024 First Quarter Financial Results and Provides Updates on Key Clinical Programs, from 7:00AM ET on Tuesday Apr 30, 2024 by Dow Jones
7:00AM ET on Tuesday Apr 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Incyte Corp | 12.1B | 16.5x | +39.11% |
Charles River Laboratories International Inc | 12.1B | 25.7x | +15.57% |
Exact Sciences Corp | 11.6B | -54.3x | --- |
United Therapeutics Corp | 11.6B | 12.4x | +8.22% |
Biomarin Pharmaceutical Inc | 15.6B | 78.0x | --- |
Medpace Holdings Inc | 12.4B | 41.4x | +35.10% |
Company Information
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company also conducts clinical development and commercial operations from its European headquarters in Morges, Switzerland and its other offices across Europe, as well as its Japanese office in Tokyo and its Canadian headquarters in Montreal. It operates in two therapeutic areas, One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of four products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs.
Contact Information
- Headquarters
- 1801 Augustine Cut-OffWILMINGTON, DE, United States 19803
- Phone
- 302-498-6700
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer
- Herve Hoppenot
- Chief Financial Officer, Executive Vice President
- Christiana Stamoulis
- Executive Vice President, Chief Scientific Officer
- Dashyant Dhanak
- Executive Vice President, General Manager, Europe
- Jonathan Dickinson
- Executive Vice President - Human Resources
- Paula Swain
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $12.1B |
|---|---|
Revenue (TTM) | $3.8B |
Shares Outstanding | 224.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.73 |
EPS | $3.29 |
Book Value | $23.14 |
P/E Ratio | 16.5x |
Price/Sales (TTM) | 3.2 |
Price/Cash Flow (TTM) | 14.6x |
Operating Margin | 18.25% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
